Abstract
In the published article, there was an error in Table 6 (Adverse events) as published. The error was found in the percentage of participants with sepsis associated with enteritis in the PEMA group. The corrected table appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Author supplied keywords
Cite
CITATION STYLE
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023). Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)(Front. Cardiovasc. Med., (2023), 10, (1094100), 10.3389/fcvm.2023.1094100). Frontiers in Cardiovascular Medicine. Frontiers Media S.A. https://doi.org/10.3389/fcvm.2023.1172664
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
